BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18023538)

  • 21. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
    Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
    Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
    Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
    BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.
    Nayak MS; Yang JM; Hait WN
    Cancer Res; 2007 Jun; 67(12):5831-9. PubMed ID: 17575151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population.
    Lum SS; Chua HW; Li H; Li WF; Rao N; Wei J; Shao Z; Sabapathy K
    Carcinogenesis; 2008 Apr; 29(4):754-61. PubMed ID: 18281248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2 and its functional polymorphism SNP309 contribute to the development of esophageal carcinoma.
    Xiao FK; Guo S; Yang F; Zhao LS; Wang LD
    J Gene Med; 2019 May; 21(5):e3086. PubMed ID: 30861607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
    Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
    Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis.
    Cao X; Zhang T; Zhao Z; Zhao T
    DNA Cell Biol; 2012 Mar; 31(3):355-9. PubMed ID: 21770737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
    Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
    Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma.
    Nakashima M; Kondo S; Shimizu Y; Wakisaka N; Murono S; Furukawa M; Yoshizaki T
    Acta Otolaryngol; 2008 Jul; 128(7):808-13. PubMed ID: 18568525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome.
    Sotamaa K; Liyanarachchi S; Mecklin JP; Järvinen H; Aaltonen LA; Peltomäki P; de la Chapelle A
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6840-4. PubMed ID: 16203772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
    Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
    Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the MDM2 SNP309 polymorphism in the initiation and early age of onset of nasopharyngeal carcinoma.
    Sousa H; Pando M; Breda E; Catarino R; Medeiros R
    Mol Carcinog; 2011 Feb; 50(2):73-9. PubMed ID: 21229604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
    Bougeard G; Baert-Desurmont S; Tournier I; Vasseur S; Martin C; Brugieres L; Chompret A; Bressac-de Paillerets B; Stoppa-Lyonnet D; Bonaiti-Pellie C; Frebourg T
    J Med Genet; 2006 Jun; 43(6):531-3. PubMed ID: 16258005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.
    Thunell LK; Bivik C; Wäster P; Fredrikson M; Stjernström A; Synnerstad I; Rosdahl I; Enerbäck C
    Melanoma Res; 2014 Jun; 24(3):190-7. PubMed ID: 24625390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
    Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
    Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
    Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
    Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.
    Okamoto K; Tsunematsu R; Tahira T; Sonoda K; Asanoma K; Yagi H; Yoneda T; Hayashi K; Wake N; Kato K
    BMC Med Genet; 2015 Aug; 16():67. PubMed ID: 26293665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
    Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
    BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.